Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis.

导出 OA

翻译打印收藏纠错

作者： Ling,Peng ^[1] ; Yina,Wang ^[1] ; Yun,Hong ^[2] ; Xianghua,Ye ^[3] ; Peng,Shi ^[4] ; Junyan,Zhang ^[5] ; Qiong,Zhao ^[6]

作者单位： Department of Thoracic Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China. ^[1] Department of Pharmacy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China. ^[2] Department of Radiotherapy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China. ^[3] Department of Medical Statistics, Children's Hospital of Fudan University, Shanghai, China. ^[4] Center for Evidence-based Medicine, Fudan University, Shanghai, China. ^[5] Bothwin Clinical Study Consultant, Bellevue, WA, USA. ^[6]

关键词 BRAF inhibitor MEK inhibitor cuSCC meta-analysis

DOI 10.18632/oncotarget.21059

PMID 29137342

发布时间 2024-06-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览11

Oncotarget

2017年8卷47期

83280-83291页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis.

Oncotarget

相似文献

Oncotarget

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis.

Oncotarget

相似文献

Oncotarget

相关期刊

检索历史清除